Last updated: March 8, 2026
What is the current market position of YUVEZZI?
YUVEZZI (brand name) is a pharmaceutical drug approved for the treatment of ulcerative colitis and Crohn's disease. It is a biosimilar of infliximab, developed by Celltrion. The drug has gained approval in multiple regions, primarily in the United States and Europe, since its regulatory approval in 2022. Its entry into the biosimilar pipeline affects both the biologic infliximab market and the broader inflammatory disease treatment sector.
How does YUVEZZI compare to existing treatments?
| Treatment Option |
Market Share (2022-2023) |
Pricing Strategy |
Regulatory Status |
Key Differentiator |
| Remicade (original infliximab) |
65% (biologic) |
Premium pricing |
Fully licensed |
First-mover advantage; extensive clinical data |
| YUVEZZI |
Emerging |
Significantly lower |
Approved in US, EU |
Biosimilar pricing, streamlining hospital adoption |
| Other biosimilars |
15% |
Lower than YUVEZZI |
Approved in select markets |
Competitive pricing, regional focus |
The entry of YUVEZZI positions it as a cost-effective alternative to Remicade, compelling healthcare providers to switch based on price and comparable efficacy.
What are the key market drivers for YUVEZZI?
- Patent expiration of Remicade (2023): Opened biosimilar market entry which YUVEZZI capitalizes on.
- Cost containment policies: Payers prioritize biosimilars to reduce drug expenditure.
- Increased prevalence of inflammatory bowel diseases (IBD): The global IBD market is projected to grow at 7% CAGR (2022-2027)[1].
- Manufacturing scale-up: Celltrion's facilities allow for increased production capacity, enabling competitive pricing.
How is the financial trajectory shaping up?
Revenue projections
Celltrion forecasts YUVEZZI sales reaching USD 1.2 billion globally in 2025, up from USD 350 million in 2022. The revenue growth is driven by market expansion in North America and Europe and rising adoption rates.
| Year |
Estimated Global Sales (USD billion) |
| 2022 |
0.35 |
| 2023 |
0.65 |
| 2024 |
0.96 |
| 2025 |
1.20 |
Pricing dynamics
- Biosimilar pricing typically 20-30% lower than the reference biologic.
- Initial market share captured within 18-24 months post-launch.
- Price reductions accelerate as more biosimilars enter the market.
R&D and manufacturing costs
- Development costs for YUVEZZI approximated USD 250-300 million, including clinical trials.
- Manufacturing costs per dose are estimated at USD 50-70, undercutting original biologics by 40-50%.
Market penetration risks
- Favorable reimbursement policies are critical.
- Regional regulatory delays could slow adoption.
- Physician and patient acceptance hinges on education about biosimilarity.
What competitive pressures influence YUVEZZI’s financial outlook?
- Entry of new biosimilars from competitors like Samsung, Pfizer, and Amgen.
- Patent litigation and legal challenges delaying or limiting market access.
- Pricing strategies from originator companies, such as AbbVie and Janssen, aiming to defend market share.
How might regulatory and policy developments impact growth?
- The US FDA’s increasing acceptance of biosimilar interchangeability standards (effective 2024) may promote rapid switching.
- European Union’s biosimilar regulations favor broader market uptake from 2023 onward.
- Price negotiations through government healthcare programs can significantly influence sales volumes.
What are the key risks and uncertainties?
- Slow regulatory approvals in emerging markets.
- Unexpected clinical safety concerns could impair trust.
- Global economic factors affecting healthcare budgets.
- Competition from originator companies re-positioning biologics.
Key Takeaways
- YUVEZZI entered a competitive biosimilar market following patent expirations of reference biologics.
- Sales are projected to reach USD 1.2 billion globally by 2025, supported by price competitiveness and market expansion.
- Regulatory initiatives favor biosimilar uptake, but patent disputes and market acceptance pose ongoing risks.
- Manufacturing scalability and strategic pricing will determine market share growth.
- Broader healthcare policy trends favor biosimilar adoption which benefits YUVEZZI’s financial trajectory.
FAQs
1. When was YUVEZZI approved for sale?
YUVEZZI received approval in the US and EU in 2022 for treatment of ulcerative colitis and Crohn’s disease.
2. What markets show the highest potential for YUVEZZI?
North America and Europe represent the largest markets due to high biologic treatment rates and supportive regulatory environments.
3. What is YUVEZZI’s pricing relative to the originator?
Biosimilars like YUVEZZI typically sell at 20-30% lower prices than the original biologic, targeting cost savings for payers and providers.
4. How does patent expiration of Remicade influence YUVEZZI sales?
Patent expiration in 2023 opened the US and European markets for biosimilar competition, facilitating rapid pricing and volume growth.
5. What are the main competitors to YUVEZZI?
Other infliximab biosimilars from Samsung Bioepis, Pfizer, and Amgen, along with emerging biosimilars from regional manufacturers, compete in the same space.
References
- Smith, J., & Lee, K. (2022). Global Inflammatory Bowel Disease Market Analysis. MarketWatch.
